Abatacept for Rheumatoid Arthritis Refractory to Tumor Necrosis Factor α Inhibition | Zendy

Mark C. Genovese | Zendy; JeanClaude Becker | Zendy; Michael Schiff | Zendy; Michael E. Luggen | Zendy; Yvonne Sherrer | Zendy; Joel Kremer | Zendy; C. Birbara | Zendy; Jane Box | Zendy; Kannan Natarajan | Zendy; Isaac Nuamah | Zendy; Tracy Li | Zendy; Richard Aranda | Zendy; David Hagerty | Zendy; Maxime Dougados | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Abatacept for Rheumatoid Arthritis Refractory to Tumor Necrosis Factor α Inhibition

Author(s) -

Mark C. Genovese,

JeanClaude Becker,

Michael Schiff,

Michael E. Luggen,

Yvonne Sherrer,

Joel Kremer,

C. Birbara,

Jane Box,

Kannan Natarajan,

Isaac Nuamah,

Tracy Li,

Richard Aranda,

David Hagerty,

Maxime Dougados

Publication year - 2005

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa050524

Subject(s) - medicine , abatacept , rheumatoid arthritis , placebo , rheumatology , arthritis , randomization , physical therapy , randomized controlled trial , gastroenterology , surgery , rituximab , pathology , lymphoma , alternative medicine

A substantial number of patients with rheumatoid arthritis have an inadequate or unsustained response to tumor necrosis factor alpha (TNF-alpha) inhibitors. We conducted a randomized, double-blind, phase 3 trial to evaluate the efficacy and safety of abatacept, a selective costimulation modulator, in patients with active rheumatoid arthritis and an inadequate response to at least three months of anti-TNF-alpha therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research